This article was originally published here
Int J Cancer. 2021 Oct 3. doi: 10.1002/ijc.33834. Online ahead of print.
Cancer is a risk factor for venous thromboembolism (VTE). Plasma tumor DNA (ptDNA) is an independent predictor of outcome in metastatic castration-resistant prostate cancer (mCRPC). We aimed to investigate the association between ptDNA and VTE in mCRPC. This prospective biomarker study included 180 mCRPC patients treated with abiraterone and enzalutamide from April 2013 to December 2018. We excluded patients with a previous VTE history and/or ongoing anticoagulation therapy. Targeted next-generation sequencing was performed to determine ptDNA fraction from pre-treatment plasma samples. VTE risk based on survival analysis was performed using cumulative incidence function and estimating sub-distributional hazard ratio(SHR). At a median follow-up of 58 months (range 0.5-111.0), we observed 21 patients who experienced VTE with a cumulative incidence at 12months of 17.1% (95% confidence interval [CI] 10.3-23.9). Elevated ptDNA, visceral metastasis, prior chemotherapy and LDH were significantly associated with higher VTE incidence compared with patients with no thrombosis (12-month estimate, 18.6 vs 3.5%, P=.0003; 44.4 vs 14.8%, P=.015; 24.7 vs 4.5%, P=.006; and 30.0 vs 13.5%, P=.05, respectively). In the multivariate analysis including ptDNA level, visceral metastases, number of lesions, serum LDH, high ptDNA fraction was the only independent factor associated with the risk of thrombosis (HR 5.78, 95%CI 1.63-20.44, P=.006). These results first suggest that baseline ptDNA fraction in mCRPC patients treated with abiraterone or enzalutamide may be associated with increased VTE risk. These patients may be followed-up more closely for the VTE risk and the need for a primary thromboprophylaxis should be taken into account in mCRPC with elevated ptDNA. This article is protected by copyright. All rights reserved.